...of PCSK9 in preclinical development that were out-licensed to an undisclosed company last year, and Liphorus Pharmaceuticals Inc....
...NASDAQ:AMGN), Thousand Oaks, Calif. Arrakis Therapeutics Inc., Waltham, Mass. Genentech Inc., South San Francisco, Calif. Liphorus Pharmaceuticals Inc....

...are making their market debuts, several companies are vying to replace them with oral candidates. Liphorus Pharmaceuticals Inc....
...Genentech Inc., South San Francisco, Calif. Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec Liphorus Pharmaceuticals Inc....
..."Nurturing killer seeds." BioCentury (2014) Martz, L. "PCSK9 peptide inhibitors." SciBX: Science-Business eXchange (2014) Sidebars Liphorus Pharmaceuticals Inc....

...ALN-PCSsc's dosing also could improve adherence over oral approaches to inhibiting PCSK9. Pfizer Inc. , Liphorus Pharmaceuticals Inc....
...Mass. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. European Society of Cardiology (ESC), Sophia Antipolis, France Liphorus Pharmaceuticals Inc....

...financial terms are not disclosed. Institut de Recherches Cliniques de Montreal (IRCM) , Montreal, Quebec Liphorus Pharmaceuticals Inc....